MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Decrease in cash and cashequivalents-$16,461K Stock-based compensationexpense$6,641K Depreciation$1,407K Income taxes$1,190K Provision for inventory$1,032K Gain on sale of assets-$904K Accounts payable$745K Non-cash operating leasecost$464K Deferred income taxes$108K Notes receivable$192K Net cash used infinancing activities-$10,347K Net cash used inoperating activities-$4,846K Net cash used in byinvesting activities-$1,239K Exchange rate impact oncash-$29K Canceled cashflow$12,491K Canceled cashflow$192K Repurchases of common stock$8,690K Cash paid for taxwithheld on vested...$1,657K Inventories$5,407K Purchases of property andequipment$1,431K Net loss-$5,056K Accounts receivable$2,180K Prepaid expenses, othercurrent and long-term...$1,728K Accrued expenses, othercurrent and long-term...-$1,339K something is missing-$956K Operating leaseliabilities-$468K Interest income on notesreceivable$179K Provision for creditlosses-$24K
Cash Flow

Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics, Inc. (ANIK)

source: myfinsight.com